fda approves first oral glp-1 obesity drug august 21 2025 The approved a pill version of the receptor agonist semaglutide (Wegovy), making it the GLP-1 agent indicated for weight loss, Novo Nordisk announced on Monday. The once-daily 25 US FDA Approves Wegovy Pill

Immune challenges : Together they support balanced immune responses and viral defense

Looking to the next generation of obesity treatments, combinations of GLP-1 with other entero-pancreatic hormones with complementary actions and/or synergistic potential (such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) are under investigation to enhance the WL and cardiometabolic benefits of GLP-1 RA

Intramuscular dexmedetomidine: an effective route of sedation preserves background activity for pediatric electroencephalograms

CoQ10 supplements protect your skin from aging by neutralizing harmful free radicals and promoting collagen production